|
Antigen/Gene or Protein Targets
|
Relevant disease (Acute Lymphoblastic Leukemia/ALL); Drug (synthetic retinoid 4-HPR: fenretinide or N-(4-hydroxyphenyl)retinamide)
|
|
Parental Line
|
CCRF-CEM
|
|
Host
|
Human
|
|
Tissue
|
Bone Marrow
|
|
Disease Keywords
|
Cancer, Acute Lymphoblastic Leukemia
|
|
Model
|
Tumour line
|
|
Relevance
|
4-HPR is a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, including leukemia cells.
|
|
Production Details
|
CCRF-CEM-R5 cell line, resistant to up to 5 mM of 4-HPR, was obtained by gradual selection. Parental CCRF-CEM cells were continuously exposed to increasing 4-HPR concentrations, starting from 0.5 mM.
|
|
Conditional
|
No
|
|
Research Area
|
Cancer, Drug Discovery & Development, Other
|
|
Growth/Phenotype Keywords
|
Cell grow in suspension
|
|
Recommended Growing Conditions
|
Cells should be grown in RPMI 1640 with 2mM L-glutamine supplemented with 10% heat inactivated FBS. Keep at 37ºC in a humidified incubator containing 5% CO2. In order to preserve their resistant intermitent exposures to 5mM 4-HPR is recomended. 4-HPR removal from R5 cell culture for up to 8 passages or 3 weeks has not shown any decrease on drug resistance although it does affect endogenous sphingolipid profile (specified in the reference paper).
|
|
Positive Control
|
Control cells are CCRF-CEM parental cells that are sensitive to higher than 1mM 4HPR
|
